MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer announces a poster presentation highlighting the results for SBP-101 as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), taking place April 8-13, 2022. The work reflects the Company’s ongoing collaboration with Johns Hopkins University School of Medicine.
Panbela Announces Poster Presentation at American Association for Cancer Research:
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here